Design Therapeutics, Inc.
DSGNNASDAQHealthcare● Active
$10.46
$-0.19(-1.78%)
Market Cap$653299948
P/E Ratio—
52W High$17.25
52W Low$3.33
Design Therapeutics, Inc. (DSGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DSGN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
-$0.29
Est. -$0.36 · +19.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
DSGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.36 | — | — | — | — | — |
| ▲ Q2 FY2026 | Apr 28, 2026 | -$0.36 | -$0.29 | +19.4% | — | — | — |
| ▲ Q1 FY2026 | Mar 9, 2026 | -$0.38 | -$0.27 | +28.9% | — | — | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.34 | -$0.30 | +11.8% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.32 | -$0.34 | -6.3% | — | — | — |
| ▼ Q2 FY2025 | May 7, 2025 | -$0.28 | -$0.31 | -10.7% | — | — | — |
| ▲ Q1 FY2025 | Mar 10, 2025 | -$0.28 | -$0.24 | +14.3% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.26 | -$0.23 | +11.5% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.36
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Beat
EPS Actual
-$0.29
EPS Est.
-$0.36
EPS Surpr.
+19.4%
Revenue
—
Q1 FY2026
Mar 9, 2026Beat
EPS Actual
-$0.27
EPS Est.
-$0.38
EPS Surpr.
+28.9%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.34
EPS Surpr.
+11.8%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.34
EPS Est.
-$0.32
EPS Surpr.
-6.3%
Revenue
—
Q2 FY2025
May 7, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.28
EPS Surpr.
-10.7%
Revenue
—
Q1 FY2025
Mar 10, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.28
EPS Surpr.
+14.3%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.23
EPS Est.
-$0.26
EPS Surpr.
+11.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.43 | $0.43 | $0.43 | 1 |
| Q3 FY2030 | $0.29 | $0.29 | $0.29 | 1 |
| Q2 FY2030 | $0.11 | $0.11 | $0.11 | 1 |
| Q1 FY2030 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q4 FY2029 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2029 | $-0.25 | $-0.25 | $-0.25 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 28, 2026 | +19.4% | $12.81 | $12.81 | +0.00% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +28.9% | $10.05 | $10.37 | +3.18% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +11.8% | $6.24 | $6.55 | +4.97% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -6.3% | $4.35 | $3.97 | -8.74% |
| ▼ Q2 FY2025 | May 7, 2025 | -10.7% | $3.63 | $3.33 | -8.26% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +14.3% | $4.92 | $4.87 | -1.02% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +11.5% | $5.94 | $5.79 | -2.53% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +16.0% | $4.74 | $4.66 | -1.69% |
Q2 FY2026+0.00%
Report Date
Apr 28, 2026
EPS Beat/Miss
+19.4%
Price Before
$12.81
Price After
$12.81
Q1 FY2026+3.18%
Report Date
Mar 9, 2026
EPS Beat/Miss
+28.9%
Price Before
$10.05
Price After
$10.37
Q4 FY2025+4.97%
Report Date
Nov 5, 2025
EPS Beat/Miss
+11.8%
Price Before
$6.24
Price After
$6.55
Q3 FY2025-8.74%
Report Date
Aug 7, 2025
EPS Beat/Miss
-6.3%
Price Before
$4.35
Price After
$3.97
Q2 FY2025-8.26%
Report Date
May 7, 2025
EPS Beat/Miss
-10.7%
Price Before
$3.63
Price After
$3.33
Q1 FY2025-1.02%
Report Date
Mar 10, 2025
EPS Beat/Miss
+14.3%
Price Before
$4.92
Price After
$4.87
Q4 FY2024-2.53%
Report Date
Nov 7, 2024
EPS Beat/Miss
+11.5%
Price Before
$5.94
Price After
$5.79
Q3 FY2024-1.69%
Report Date
Aug 5, 2024
EPS Beat/Miss
+16.0%
Price Before
$4.74
Price After
$4.66
Avg Beat Reaction+0.49%
Avg Miss Reaction-8.50%
Beat Rate6 / 8 quarters
Largest Move-8.74% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DSGN ends December
Design Therapeutics, Inc. (DSGN) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $-0.29 — beating the analyst consensus of $-0.36 by +19.4%. DSGN has beaten EPS estimates for 3 consecutive quarters. The next DSGN earnings date is expected around September 1, 2026.
Each quarter, investors track DSGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DSGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DSGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DSGN earnings · 5 questionsDesign Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. DSGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DSGN historically reports after market close (AMC).
DSGN earnings datewhen is DSGN earningsDSGN next earnings datewhen does DSGN report earningsDSGN earnings calendar
▸ Source: FMP · Design Therapeutics, Inc. SEC filings · US GAAP · Design Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026